Current Headlines

  1. BenchSci Announces Two-Year Enterprise Agreement With Argenx To Advance AI-Driven Preclinical Drug Discovery 9/2/2026

    BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization.

  2. Biocytogen Enters Into Non-Exclusive Licensing Agreement With Qilu Pharmaceutical For A Fully Human VHH Antibody To Support Innovative Drug Development In Neuroscience 9/2/2026

    Biocytogen Pharmaceuticals (Beijing) Co., Ltd. today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule.

  3. Insilico Medicine Included In The HKEX Tech 100 Index, Drawing Attention To Opportunities In AI Value Chain 9/2/2026

    Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in the HKEX Tech 100 Index, following the methodology enhancements to broaden the exposure to "emerging technology trends, including opportunities across the AI value chain", announced on 18 August 2026.

  4. NorthStrive Biosciences Expands AI-Driven Drug Discovery Program With Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination For Potential Cardiac Disease And Obesity Therapeutic Applications 9/1/2026

    NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) ("PMGC" or the "Company"), today announced the execution of a First Amendment to its Development and License Agreement (the “Amendment”) with strategic partner Yuva Biosciences, Inc. ("Yuva Biosciences").

  5. QC Ware And IonQ Demonstrate High-Precision Hybrid Quantum Workflow For Drug Discovery 9/1/2026

    QC Ware today announced a technology demonstration of a hybrid quantum-classical chemistry workflow using its Promethium® platform and IonQ's Forte trapped-ion quantum computer via Amazon Braket.

  6. Weave Bio Announces Collaboration With Takeda To Deploy AI-Native Regulatory Automation Across Key Drug Development Activities 9/1/2026

    Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets.

  7. Devonian Health Group Strengthens Thykamine™ Manufacturing Platform With Validated Chemical-Composition Fingerprinting And Biological Potency Assay 9/1/2026

    Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announced the successful independent validation and integration of key analytical and biological quality-control technologies into the extraction and manufacturing process for Thykamine™, the Company's lead active botanical drug candidate.

  8. FluoSphera Licenses Debiopharm's AbYlink Technology For 3D Antibody Characterization While Leveraging Leica Microsystems Viventis Deep Imaging Capabilities 9/1/2026

    Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases and FluoSphera, a Swiss biotechnology company developing advanced in vitro platforms to improve the prediction of drug efficacy and safety, today announced a new license agreement for use of AbYlink, Debiopharm’s proprietary antibody conjugation technology.

  9. OneMedNet's iRWD Platform Enables Rapid Feasibility-To-Delivery For Leading AI-Driven Drug Development Company 8/31/2026

    OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced a new agreement to deliver de-identified, full-fidelity clinical Real-World Data to a leading AI-driven drug development company.

  10. IDEAYA Biosciences Announces Successful FDA Type C Meeting For IDE849, DLL3 TOP1 ADC, On Phase 3 Registrational Trial Design For Potential Accelerated And Full Approval In Extensive Stage Small Cell Lung Cancer 8/31/2026

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type C meeting to determine the Phase 3 registrational trial design for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in extensive stage small cell lung cancer (ES-SCLC).